Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells

Leukemia Research

Volumn 28, Issue 5, 2004, Pages 517-524

  Lee, Je Jung ^a,b   Nam, Chan Eun ^b   Nam, Jong Hee ^a   Lee, Hyun Chul ^a   Chung, Ik Joo ^a,b   Park, Myong Suk ^a   Choi, Bo Hwa ^a   Song, Won Hyun ^a   Lee, Il Kwon ^b   Park, Kyeong Soo ^b   Kook, Hoon ^a   Hwang, Tai Ju ^a   Takei, Masao ^c   Takaue, Yoichi ^d   Kim, Hyeoung Joon ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c RESEARCH CENTER BORSTEL   (Germany)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Dendritic cells; Immunotherapy; Stem cells; Transplantation

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; T6 ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL LYSATE; CELL STIMULATION; CYTOTOXICITY; DENDRITIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 11144353858     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.08.018     Document Type: Article

References (26)

1. Cullis J.O., Jiang Y.Z., Schwarer A.P., Hughes T.P., Barrett A.J., Goldman J.M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 79:1992;1379-1381.
2. Drobyski W.R., Keever C.A., Roth M.S., Koethe S., Hanson G., McFadden P.et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 82:1993;2310-2318.
3. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W.et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow-grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:1995;2041-2050.
4. Okumura H., Takamatsu H., Yoshida T. Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation. Br. J. Haematol. 93:1996;386-388.
5. Porter D.L., Roth M.S., Lee S.J., McGarigle C., Ferrara J.L., Antin J.H. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 18:1996;975-980.
6. Baron F., Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion. 40:2000;468-476.
7. Marijt W.A., Falkenburg J.H. Specific T cell therapy in leukemia. J. Hematother. Stem Cell Res. 10:2001;493-500.
8. Brenner M, Porcelli S. Antigen presentation: a balanced diet. Science 1997;277:332.
9. Cardoso A.A., Seamon M.J., Afonso H.M., Ghia P., Boussiotis V.A., Freeman G.J.et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 90:1997;549-561.
10. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245-3287.
11. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
12. Reid D.C. Dendritic cells and immunotherapy for malignant disease. Br. J. Haematol. 112:2001;874-887.
13. Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 93:1999;2336-2341.
14. Pawlowska A.B., Hashino S., McKenna H., Weigel B.J., Taylor P.A., Blazar B.R. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood. 97:2001;1474-1482.
15. Lee J.J., Takei M., Hori S., Inoue Y., Harada Y., Tanosaki R.et al. The role of PGE2 in the differentiation of dendritic cells: how do dendritic cells influence T cell polarization and chemokine receptor expression? Stem Cell. 20:2002;448-459.
16. Choudhury B.A., Liang J.C., Thomas E.K., Flores-Romo L., Xie Q.S., Agusala K.et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 93:1999;780-786.
17. Harrison B.D., Adams J.A., Briggs M., Brereton M.L., Yin J.A. Stimulation of autologous proliferative and cytotoxic T-cell responses by leukemic dendritic cells derived from blast cells in acute myeloid leukemia. Blood. 97:2001;2764-2771.
18. Koski G.K., Schwartz G.N., Weng D.E., Gress R.E., Engels F.H., Tsokos M.et al. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood. 94:1999;1359-1371.
19. Waclavicek M., Berer A., Oehler L., Stockl J., Schloegl E., Majdic O.et al. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br. J. Haematol. 114:2001;466-473.
20. Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. Immunology. 107:2002;20-27.
21. Goker H., Haznedaroglu I.C., Chao N.J. Acute graft-vs-host disease: pathobiology and management. Exp. Hematol. 29:2001;259-277.
22. MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br. J. Haematol. 110:2000;12-17.
23. Mutis T., Blokland E., Kester M., Schrama E., Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood. 100:2002;547-552.
24. Shteper P.J., Ben-Yehuda D. Molecular evolution of chronic myeloid leukaemia. Semin. Cancer Biol. 11:2001;313-323.
25. Spisek R., Chevallier P., Morineau N., Milpied N., Avet-Loiseau H., Harousseau J.L.et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of non-leukemic origin. Cancer Res. 62:2002;2861-2868.
26. Galea-Lauri J., Darling D., Mufti G., Harrison P., Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell - leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51:2002;299-310.